Federal Court delists Regeneron patent, clearing path for Amgen biosimilar launch

By Karunjit Singh ( January 29, 2025, 4:17 PM EST) -- The Federal Court has ruled that a patent for the treatment of age-related macular degeneration (AMD) owned by New York-based Regeneron Pharmaceuticals is ineligible for inclusion on the patent register, clearing a barrier for Mississauga-based Amgen Canada to launch a biosimilar product....